Sign in
SUPN Stock Price, Chart, Stats & News
Supernus Pharmaceuticals Inc
Save
2.58B
Market cap
–
Current P/E
20.16x
Forward P/E
SUPN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 85.54% |
Operating margin | -6.19% |
Pretax margin | -6.82% |
Net margin | -5.36% |
Effective tax rate | 21.37% |
ROA | -0.00% |
ROE | -0.01% |
D/E | 0.03x |
Interest coverage ratio | – |
SUPN valuation
P/E | – |
P/S | 3.97x |
P/B | 0.00x |
P/CF | 60.00x |
P/FCF | 62.00x |
P/OCF | 60.00x |
PEG | 0.69x |
EV multiple | 961.73x |
About
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults.
Similar securities
Based on sector and market capitalization
Report issue